Pharmaceutical giant AstraZeneca took a beating in 2016. The company likely hopes 2017 will provide more opportunities for growth, but the lasting effects of the previous year might weigh...
Healthcare giant Johnson & Johnson (J&J) and its subsidiary Janssen Pharmaceuticals plan to ring in the new year with results from a seven year long study testing the effectiveness...
The high blood pressure medication Benicar will face generic competition this year, effectively ending its longstanding stranglehold on the market. However, manufacturer Daiichi Sankyo’s trouble with Benicar is merely...
The relationship between doctors and pharmaceutical companies has many restrictions. Pharmaceutical companies are not allowed to pay doctors kickbacks for prescribing certain medications. However, companies are allowed to pay...
It’s been a rough year for healthcare giant Johnson & Johnson (J&J). While the company is likely accustomed to fighting a high number of product liability lawsuits, 2016 saw...
The U.S. Food and Drug Administration (FDA) is often criticized for stifling medical innovation, but a conference that took place earlier this week has some worried the federal agency...
Two years ago the federal government began an investigation into price fixing by approximately twelve large pharmaceutical companies. The antitrust investigation targeted more than two-dozen generic drugs and a...
While hospitals are generally safe places, they contain some of the world’s smallest and most dangerous pathogens. Sometimes called a “super bug,” Methicillin-resistant Staphylococcus aureus (MRSA) is bacteria resistant...
When AstraZeneca developed Nexium in the 1990s, the drug was intended to treat various gastrointestinal and indigestion symptoms and conditions. Today, the drug is one of the most popular...
Pharmaceutical giant Mylan recently announced it received FDA approval of a generic version of Daiichi Sankyo’s blood pressure medication Benicar. Mylan likely hopes its version doesn’t face the harsh...
